TPG Capital, L.P.
+27.03%
3か月リターン
$6.060
-0.249 (-4.11%)終値時点
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
BDJ is a good buy right now due to its attractive 8.1% dividend yield and a solid 32% increase in dividends over the past decade, indicating strong income potential. Additionally, it is currently trading at an 8.2% discount, which could lead to price appreciation as market confidence improves. The main risk is its recent performance with a 1-day change of -0.31%, suggesting some short-term volatility.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。